• Harrow received FDA clearance of its Investigational New Drug application for TRIESENCE, allowing a Phase 3 clinical trial to proceed.
• This regulatory decision marks a key clinical milestone for the company’s ophthalmic drug pipeline.
• The TRIESENCE Phase 3 program adds a new pillar to Harrow's story beyond previously discussed earnings and financial guidance.

Harrow, trading on NasdaqGM:HROW, now has a fresh clinical catalyst in play alongside its existing commercial portfolio. The stock last closed at $31.21, with returns down 18.4% over the past week, down 23.2% over the past month, and down 37.5% year to date. Even with that recent pressure, the stock is up 9.9% over 1 year, 46.4% over 3 years, and 211.2% over 5 years. These historical figures provide context for how the market has treated Harrow's long term story.

For investors watching Harrow, the Phase 3 clearance for TRIESENCE adds a clinical angle that is separate from near term earnings swings. As this trial progresses, attention may focus on how TRIESENCE could broaden Harrow's ophthalmic footprint and potentially diversify its revenue base beyond current product cycles.

Stay updated on the most important news stories for Harrow by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Harrow.

The FDA’s clearance for Harrow’s Phase 3 TRIESENCE trial gives the company another clinical asset that sits alongside its commercial revenue guidance story. TRIESENCE is already part of Harrow’s ophthalmic portfolio, and a Phase 3 program in ocular inflammation and pain after cataract surgery targets a large, procedure driven market where players such as Alcon and Bausch + Lomb are active. For you as an investor, this matters because it ties Harrow’s near term revenue guidance of US$71 million to US$81 million for Q2 2026 and US$350 million to US$365 million for 2026 to a longer term pipeline that could support the product mix beyond VEVYE and IHEEZO. The trial also arrives shortly after a Q1 2026 quarter where revenue was US$44.2 million and the company reported a net loss of US$27.6 million, so the focus now is whether clinical execution and future TRIESENCE data can eventually help offset the current loss profile and heavy dependence on a few branded products.

How This Fits Into The Harrow Narrative

• The Phase 3 TRIESENCE program supports the narrative that Harrow can expand its ophthalmic portfolio into new indications and broaden the patient base beyond dry eye and anesthesia.
• The need to fund and run another late stage trial adds to execution demands at a time when Q1 2026 losses widened, which could challenge assumptions about how quickly margins improve.
• The TRIESENCE Phase 3 opportunity in post cataract inflammation may not be fully reflected in existing narratives that focus more heavily on VEVYE, IHEEZO and biosimilar assets.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Harrow to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Heavier R&D and trial spending for TRIESENCE comes on top of a Q1 2026 net loss of US$27.6 million, so cash usage and future financing needs remain key to watch.
• ⚠️ Harrow still relies on a concentrated set of products, so if TRIESENCE data disappoints or timelines slip, that concentration risk highlighted by analysts stays in focus.
• 🎁 A successful TRIESENCE Phase 3 in ocular inflammation and pain could open a sizable procedure driven market and reduce reliance on VEVYE specific reimbursement and pricing dynamics.
• 🎁 The Phase 3 clearance aligns with Harrow’s push to broaden its ophthalmic pipeline, which may support revenue diversification alongside guided growth from VEVYE, IHEEZO and other launches.

What To Watch Going Forward

From here, keep an eye on TRIESENCE Phase 3 timelines, trial design details and any interim updates, especially how Harrow frames the commercial opportunity versus existing post cataract therapies from larger peers. It also makes sense to track whether management continues to reaffirm 2026 revenue guidance as trial costs ramp and to compare future quarters to Q1 2026 revenue of US$44.2 million and the reported loss, to see if operating leverage starts to improve while the pipeline advances.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Harrow, head to the community page for Harrow to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.